Status:
COMPLETED
Felodipine Event Reduction Study
Lead Sponsor:
Chinese Academy of Medical Sciences
Collaborating Sponsors:
Shanxi Kangbao Pharmaceutical company
Beijing Hypertension League Insititute
Conditions:
Hypertension
Eligibility:
All Genders
50-79 years
Phase:
NA
Brief Summary
FEVER is an investigator-designed, prospective, multicentre,double-bind, randomized, placebo-controlled,parallel-group trial. The primary objective is to compare the long-term effects on the incidence...
Eligibility Criteria
Inclusion
- SBP of 210 mmHg or less and DBP less than 115 mmHg if under antihypertensive treatment; SBP 160-210 mmHg or DBP 95-115 mmHg if untreated. Presence of at least one or two risk factors or cardiovascular diseases Informed consent obtained
Exclusion
- stroke or myocardial infarction during the previous 6 months; secondary hypertension; unstable angina; cardiomyopathy or significant valvular disease; serum creatinine greater than 178 mmol/l (2.0 mg/dl); gout; uncontrolled diabetes(fasting plasma glucose \> 10 mmol/l, 180 mg/dl despite therapy); serious pulmonary or hepatic disease; known contraindications to study drugs; unwillingness to cooperate
Key Trial Info
Start Date :
April 1 1998
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2004
Estimated Enrollment :
9800 Patients enrolled
Trial Details
Trial ID
NCT01136863
Start Date
April 1 1998
End Date
June 1 2004
Last Update
June 25 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fu Wai Hospital
Beijing, China, 100037